Kristi Rosa

Associate Editorial Director, OncLive®
Kristi Rosa joined MJH Life Sciences in 2016 and has since held several positions within the company. She helped launch the rapidly growing infectious disease news resource Contagion, strengthened the Rare Disease Report, of HCPLive, and now oversees OncLive and its flagship publication OncologyLive. Prior to working at the company, she served as lead copywriter and marketing coordinator at The Strand Theater. Email: krosa@onclive.com

Articles

Taletrectinib Demonstrates Durable Responses in TKI-Naive and -Pretreated ROS1+ NSCLC

September 8th 2025

Taletrectinib delivered high response rates and durable benefit with manageable safety in ROS1-positive non–small cell lung cancer.

Ifinatamab Deruxtecan Elicits Responses in Previously Treated Extensive-Stage Small Cell Lung Cancer

September 7th 2025

Ifinatamab deruxtecan was efficacious and had a manageable safety profile in patients with previously treated extensive-stage small cell lung cancer.

Zidesamtinib Data Align With Clinical Expectations in Pretreated ROS1+ Advanced NSCLC

September 7th 2025

The brain-penetrant, TRK-sparing, ROS1-selective TKI zidesamtinib was active and safe in patients with advanced ROS1+ non–small cell lung cancer.

Frontline Osimertinib Plus Chemo Significantly Improves OS in EGFR-Mutated Advanced NSCLC

September 7th 2025

Updated FLAURA2 OS data confirm osimertinib plus chemotherapy as a first-line SOC treatment in EGFR-mutated advanced NSCLC.

Five Under 5: Top Oncology Videos for the Week of 8/31

September 7th 2025

The top 5 OncLive videos of the week cover insights in sarcoma, colorectal cancer, acute lymphoblastic leukemia, renal cell carcinoma.

CheckMate 77T QOL Data Further Support Perioperative Nivolumab in Resectable NSCLC

September 7th 2025

Perioperative nivolumab maintained HRQOL and decreased the risk of deterioration vs placebo in patients with stage III N2 NSCLC.

Continuing Osimertinib Plus Chemo After Progression Improves PFS in EGFR-Mutated NSCLC

September 6th 2025

COMPEL data support osimertinib plus chemotherapy in EGFR-mutated NSCLC after non-CNS progression on frontline osimertinib.

Frontline Iza-Bren Plus Osimertinib Elicits 100% ORR in EGFR-Mutant NSCLC

September 6th 2025

First-line iza-bren plus osimertinib demonstrated a manageable safety profile with preliminary antitumor activity in EGFR-mutant NSCLC.

Mosunetuzumab Plus Polatuzumab Vedotin Triples Median PFS in Transplant-Ineligible LBCL

September 6th 2025

A chemotherapy-free regimen of mosunetuzumab and polatuzumab vedotin improved PFS and response rates vs R-GemOx in relapsed/refractory LBCL.

Loncastuximab Tesirine Plus Glofitamab Shows Early Safety and Efficacy in R/R DLBCL

September 6th 2025

Loncastuximab tesirine plus glofitamab demonstrated early promise in patients with relapsed or refractory large B-cell lymphoma.

Dr Issa on Testing for NPM1 or KMT2A Alterations in AML

September 6th 2025

Ghayas C. Issa, MD, MS, discusses the optimal timing of and approaches to genetic testing for NPM1 and KMT2A alterations in AML.

The OncFive: Top Oncology Articles for the Week of 8/31

September 6th 2025

FDA grants type A meeting to discuss RP1 BLA in melanoma, CBP/p300 bromodomain inhibitor gets fast track status in NSCLC, and more.

Ventana Assay Earns CE IVDR Approval in EU as Companion Diagnostic in HER2-Expressing Breast and Biliary Tract Cancers

September 5th 2025

The VENTANA HER2 (4B5) test earned CE-IVDR approval in Europe to assess HER2 status in metastatic breast cancer and biliary tract cancer.

Ziftomenib With 7+3 Shows Early Promise in Newly Diagnosed NPM1-Mutated/KMT2A-Rearranged AML

September 4th 2025

The combination of ziftomenib and cytarabine/daunorubicin showed a manageable safety profile with early efficacy in NPM1-mutated and KMT2A-rearranged AML.

Tisotumab Vedotin Approved in Hong Kong for Recurrent or Metastatic Cervical Cancer

September 3rd 2025

Tisotumab vedotin is cleared in Hong Kong for the treatment of select patients with cervical cancer.

OncLive’s August Roundup of Key FDA Approvals in Oncology: 3 Decisions to Know

September 2nd 2025

Here is your guide to all therapeutic options that were cleared by the FDA in August 2025 spanning tumor types.

Five Under 5: Top Oncology Videos for the Week of 8/24

August 31st 2025

The top 5 OncLive videos of the week cover insights in lung cancer, ovarian cancer, breast cancer, and prostate cancer.

The OncFive: Top Oncology Articles for the Week of 8/24

August 30th 2025

The FDA has cleared a 3-month subcutaneous depot formulation of leuprolide mesylate in prostate cancer, gedatolisib NDA is under review in breast cancer, and more.

Ivonescimab Plus Chemo Boosts OS in Pretreated EGFR+ NSCLC

August 26th 2025

Ivonescimab plus chemotherapy improved overall survival in previously treated, advanced non–small cell lung cancer harboring EGFR mutations.

Trastuzumab Deruxtecan Approved in Japan for HER2-Low or -Ultralow Metastatic Breast Cancer

August 26th 2025

Trastuzumab deruxtecan has been approved in Japan for patients with HR+, HER2-low or -ultralow metastatic breast cancer.

NEXT PAGE
PREVIOUS PAGE